Thomas C. Chen, MD, PhD

Professor of Neurological Surgery

Director, Brain Tumor Center at Keck Hospital of USC

Director, Neurosurgery, Good Samaritan Hospital

Director, USC Neurological Surgery Satellite Operations

Image of Thomas C. Chen, MD, PhD
Is this your profile? Click to edit

Overview

Dr. Chen’s goal is to make USC Neuro-oncology the leader in innovative treatments for brain and spine tumors. As a result, emphasis is placed on translating new findings made in the laboratory to clinical trials. Laboratory efforts are directed toward research on endoplasmic reticulum stress, understanding glioblastoma endothelial cells, and development of novel anti-invasion therapies such as vicrostatin, a unique disintegrin made at USC, and noscopine. Technological advances that may be used in the treatment of brain or spine tumors are being developed, patented, and will soon be highlighted. Novel clinical trials currently available or soon to be available at USC include anti-EGFRviii vaccine therapy, IL-4-pseudomonas exotoxin for convection enhanced delivery, and anti-tenascin brachytherapy. Surgical therapy is based on the newest techniques in microdissection and image guidance using neuronavigational therapy, with a soon to be added intraoperative MRI scanner. Spine oncology is especially unique as Dr. Chen is one of the few fellowship trained spine surgeons focused on spine cancer. Decisions on therapy are made through tumor board via a multi-disciplinary team dedicated to neuro-oncology including neurosurgery, medical oncology, radiation oncology, neuropathology, and neuro-radiology.

Research Funding

  • Development of NEO212, A Novel Oral Drug for the Treatment of Acute Myeloid Leukemia
    NIH · R41CA271879 · Aug 7, 2025 – Jul 31, 2026 · Role: Principal Investigator
  • Developing a Clinically Relevant Radiosensitizer for Temozolomide-resistant Gliomas
    NIH · R42CA246902 · Apr 1, 2020 – Aug 31, 2027 · Role: Principal Investigator
  • Developing a clinically relevant radiosensitizer for temozolomide-resistant gliomas
    NIH · R41CA246902 · Apr 1, 2020 – Mar 31, 2021 · Role: Principal Investigator
  • Innovative Nose-to-Brain Anticancer Drug Transport Facilitated by NEO100
    NIH · R41CA217551 · Apr 1, 2018 – Mar 31, 2020 · Role: Principal Investigator
  • Temozolomide Perillyl Alcohol Conjugate as Treatment for Recurrent Malignant Brain tumors
    NIH · R41CA192419 · Jul 1, 2016 – Jun 30, 2017 · Role: Principal Investigator
  • A Novel Brachytherapy Agent for GBM
    NIH · R41CA165626 · Aug 29, 2013 – Jul 28, 2015 · Role: Principal Investigator

Publications

  • Existing knowledge, myths, and perceptions about hepatitis B and liver cancer within highly impacted immigrant communities. J Virus Erad. 2024 Jun; 10(2):100379.. View in PubMed
  • Activation of Epstein-Barr Virus’ Lytic Cycle in Nasopharyngeal Carcinoma Cells by NEO212, a Conjugate of Perillyl Alcohol and Temozolomide. Cancers (Basel). 2024 Feb 26; 16(5).. View in PubMed
  • Enhancing brain entry and therapeutic activity of chimeric antigen receptor T cells with intra-arterial NEO100 in a mouse model of CNS lymphoma. J Neurosurg. 2024 06 01; 140(6):1549-1557.. View in PubMed
  • A cross-sectional study to test equivalence of low- versus intermediate-flip angle dynamic susceptibility contrast MRI measures of relative cerebral blood volume in patients with high-grade gliomas at 1.5 Tesla field strength. Front Oncol. 2023; 13:1156843.. View in PubMed
  • Using machine learning and big data for the prediction of venous thromboembolic events after spine surgery: A single-center retrospective analysis of multiple models on a cohort of 6869 patients. J Craniovertebr Junction Spine. 2023 Jul-Sep; 14(3):221-229.. View in PubMed
  • From the groin to the brain: a transfemoral path to blood-brain barrier opening. Oncotarget. 2023 05 04; 14:413-416.. View in PubMed
  • Intranasal Delivery of miR133b in a NEO100-Based Formulation Induces a Healing Response in Spinal Cord-Injured Mice. Cells. 2023 03 18; 12(6).. View in PubMed
  • NEO212, a Perillyl Alcohol-Temozolomide Conjugate, Triggers Macrophage Differentiation of Acute Myeloid Leukemia Cells and Blocks Their Tumorigenicity. Cancers (Basel). 2022 Dec 09; 14(24).. View in PubMed
  • Applicability of Pharmacogenomically Guided Medication Treatment during Hospitalization of At-Risk Minority Patients. J Pers Med. 2021 Dec 10; 11(12).. View in PubMed
  • Surviving Over a Decade With Glioblastoma: A Clinical Course Characterized by Multiple Recurrences, Numerous Salvage Treatments, and Novel Use of Cesium-131 Tiles. Cureus. 2021 Nov; 13(11):e19573.. View in PubMed